The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
